Track record · closed signal

Boston Scientific Corporation (BSX) — closed signal from November 8, 2025

Partial Published before the outcome was known, scored automatically when the window closed on February 6, 2026.

Predicted vs. what happened

BSX price · publication thesis → realized outcomesplit-adjusted

$99.00 – $100.50Entry zone — fair-value band

$100.02Published — price the day we called it

$120.02Target — the price the thesis aimed for

$105.65Peak — highest point inside the window, not a realized return

$76.27Window close — end-of-window price, context only

What happened

Partial

Reached 28% of the predicted growth at its peak, without hitting the target.

Peak price

$105.65

peak on November 13, 2025 — not a realized return

Peak gain

+5.6%

peak, from the publication price

Window close

$76.27

end-of-window price, context only

Days to target

—

Window

November 8, 2025 – February 6, 2026

The thesis — published November 8, 2025

Predicted growth

+20%

over the measurement window

Target price

$120.02

the price the thesis aimed for

Entry zone

$99.00 – $100.50

the fair-value band we waited for

Price at publication

$100.02

published November 8, 2025

Confidence

64%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

The stock dipped and then steadied. The company confirmed the $88M BioEnvelope purchase from Elutia, adding a product that fits its heart-device lineup. Investor mood is positive, and demand for medical tech has stayed reliable. In a gently rising market, strong healthcare names often get priced higher after short pauses. Plan to buy near the recent average price and look for more buyers and higher lows.

Primary drivers

Stock looks washed out, and the recent average price has steadied lately.
Elutia's $88M BioEnvelope deal adds another product to the lineup.
Demand for medical devices has stayed steady even as markets wobble.
A firmer market could push investors to value this strong company higher.

How it played out

BSX: target was not reached

Lyra published BSX at $100.02 on 2025-11-08, with 20% expected growth over a short-term window. The thesis pointed to a dipped stock that had steadied, the $88M BioEnvelope purchase from Elutia, steady medical-device demand, and a firmer market that could bring in more buyers and higher lows.

Inside the window, BSX rose to $105.65 on 2025-11-13, a 5.6% peak gain. It stayed below the $120.02 target and never reached it. By 2026-02-06, it ended at $76.27. The thesis only partially played out: the early lift was real, but the expected 20% move did not happen.

What happened during the window

On 2026-02-04, Barron's reported that Boston Scientific posted adjusted earnings of $0.80 a share and net sales of $5.29 billion for the fourth quarter. On the same date, Investor's Business Daily reported that electrophysiology sales came in at $890 million, up 35% year over year, while Boston Scientific stock fell 17.6% to 75.50.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All BSX signals